3N Bio

3N Bio develops a quick and simple test able to detect antimicrobial resistance independent of the drug resistance mechanism used. 

3N Bio develop a quick and simple test able to detect antimicrobial resistance independent of the drug resistance mechanism used. 

The rapid emergence of antibiotic-resistant bacteria and multidrug-resistant pathogenic fungi pose a threat to global health. If no urgent actions are taken, by 2050, antimicrobial resistance (AMR) will cause an estimated loss of 10 million lives and $US100 trillion. Fast and accurate diagnosis of antimicrobial resistant strains is key to contain the rise of AMR, limit its spread and provide adequate treatment to patients.

3N Bio development quick and simple tests able to detect antimicrobial resistance independent of the drug resistance mechanism used. The aim is to provide fast diagnosis for bacterial infections and provide actionable recommendation for antibiotic usage. The final goal is to  accelerate diagnosis,  improve patient survival, and contribute to individualized and rational use of antibiotics.

 
Contact:  info@3n-bio.com

Follow 3N Bio on LinkedIn here.

Read about 3N Bio here.

 

Deep Tech Diagnostics DRIVE incubator company Infection Research Tools
Go back